Clinical Trial Detail

NCT ID NCT02443883
Title A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

stomach cancer

gastroesophageal junction adenocarcinoma

Therapies

Ramucirumab

Age Groups: adult

No variant requirements are available.